Event Overview:
In early 2016, President Barack Obama announced a $215 million national Precision Medicine Initiative including a national database of genetic information of one million people in the United States. What came before this presidential announcement has been the unfolding of a scientific revolution leading to medical treatments for individuals based on their genetic information. Pharmacogenomics links drug treatments to your DNA to develop safer and more effective drug therapy to treat diseases that range from cancer to depression. Please join the ACCJ Globalization Committee in welcoming the father of pharmacogenomics, Dr. Richard Weinshilboum, and the distinguished Dr. Liewei Wang to speak on past efforts at the Mayo Clinic and their colleagues at institutions around the world. Pharmacogenomics has been able to crack the code to address important issues such as why women with breast cancer develop drug-related toxicity or fail to respond to therapy, and why some children with childhood leukemia develop life-threatening adverse drug reactions. The successes of pharmacogenomics have been an important stepping stone to the establishment of the national Precision Medicine Initiative. Dr. Weinshilboum and Dr. Wang are in Japan as part of a collaborative relationship with the RIKEN Center for Genomic Medicine in Yokohama under the auspices of the Mayo Pharmacogenomics Research Program. Bryan A. Norton, Chair Jakob Edberg, Piyasena C. Perera, Vice Chairs A. Barry Hirschfeld, Jr., Board Liaison ACCJ Globalization Committee (Committee Coordinator: G. Ohyama) For any inquiries, please email programs@accj.or.jp William Bishop, Chair John W. Carlson III, Izumi Hamada, Yuko Kidoguchi, Takeo Morooka, R. Byron Sigel, Vice Chairs John D. Harris, Board Liaison ACCJ Healthcare Committee NOTE 1: This event is OFF THE RECORD. NOTE 2: If you cancel after the stated deadline, the full meeting fee will be charged to your account. Sorry, no substitutions or walk-ins. Comments are closed.
|
Proudly powered by Weebly
